A high-throughput single-cell ATAC-seq method developed by Stanford University now available on the SMARTer™ ICELL8® Single-Cell System from Takara Bio USA, Inc.

MOUNTAIN VIEW, Calif., Sept. 18, 2018 /PRNewswire/ -- Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., is proud to announce that researchers from William Greenleaf's laboratory (Stanford University) have collaborated with TBUSA to develop a high-throughput single-cell ATAC-seq (assay for transposition of accessible chromatin) method on the SMARTer ICELL8 Single-Cell System. 

The researchers isolated and dispensed multiple hematopoietic cell types onto a 5,184-nanowell chip. Automated imaging identified ~2,300 single, live-cell-containing nanowells which were selected for on-chip generation of ATAC-seq libraries. They reported robust clustering of single cells by hematopoietic cell type. Sandy Klemm, a postdoctoral researcher in the Greenleaf lab, marveled, "We've been so impressed with how quickly Takara Bio was able to collaborate with us in transitioning from proof-of-concept to applying our ATAC-seq protocol to the ICELL8 single-cell system within six months."

"We are very pleased to have been part of this collaboration," said Carol Lou, President of Takara Bio USA, Inc. "Powerful applications, like ATAC-seq, help researchers further our understanding of a wide range of biological processes. It is exciting to see how the SMARTer ICELL8's open, flexible platform can accelerate these cutting-edge technologies and further enhance understanding of single-cell biology."  

About Takara Bio
Takara Bio USA, Inc. (TBUSA; formerly Clontech Laboratories, Inc.) is a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes kits, reagents, and instruments for life sciences research applications, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification, and automated sample preparation.

SOURCE Takara Bio USA, Inc.

Related Links

http://www.clontech.com